- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03270891
Pharmacogenomic Testing in Primary Care
Determining the Feasibility, Acceptability, and Preliminary Effectiveness of Pharmacogenomic Testing in Primary Care
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Physician participants
Inclusion criteria:
- Be a practicing physician at a University of Michigan Department of Family Medicine clinic
- Be willing to use PGx test results for their patients enrolled in the study
- Be willing to allow study staff to contact their patients
- Self-report that they are willing to prescribe antidepressants
Exclusion criteria:
-Do not meet inclusion criteria
Patient Participants
Inclusion:
- Be a patient of a participating physician
- Have a new prescription for one of the following antidepressant medications: citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Prozac Weekly, Rapiflux, Sarafem, Selfemra), fluvoxamine (Luvox, Luvox CR), paroxetine (Paxil, Paxil CR), sertraline (Zoloft), duloxetine (Cymbalta, Irenka), venlafaxine (Effexor), venlafaxine XR (Effexor XR), nortriptyline (Aventyl, Pamelor), bupropion (Forfivo XL, Wellbutrin, Wellbutrin SR, Wellbutrin XL), mirtazapine (Remeron, Remeron Soltab), or vortioxetine (Trintellix)
- Be willing to undergo PGx testing via single tube blood draw
Exclusion:
- Do not speak English
- Have previously undergone PGx testing
- Are unable to provide their own consent to participate in the study
- Have been taking the new antidepressant prescription for longer than 4 weeks (prior to screening)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Delayed intervention (control arm)
Patients in this arm will have PGx test results made available to physicians 3 months after study enrollment
|
A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety.
The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
Other Names:
|
Experimental: PGx Test
Patients in this arm will have PGx test results made available to physicians as soon available after enrollment.
|
A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety.
The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Count of Participants Prescribed Antidepressant Medication
Time Frame: Baseline, 3 months, 6 months, and 9 months
|
Count of participants who have been prescribed antidepressant medications which are not contraindicated
|
Baseline, 3 months, 6 months, and 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Symptom Severity - Patient Health Questionnaire (PHQ-8)
Time Frame: Baseline and 6 months
|
Change in PHQ-8 scores.
The PHQ-8 is an 8-item participant-report measure for screening for depression and for establishing depression severity.
The total score ranges from 0-24, with a higher score indicating greater depression symptom severity.
|
Baseline and 6 months
|
Change in Symptom Severity - General Anxiety Disorder - 7 (GAD 7)
Time Frame: Baseline and 6 months
|
The GAD-7 is a self-administered assessment for general anxiety disorder.
The total score for the seven items ranges from 0 to 21.
Higher values represent a worse outcome.
|
Baseline and 6 months
|
Change in Adherence to Refills and Medication Scale (ARMS) Scores
Time Frame: Baseline and 6 months
|
Change in medication adherence: The Adherence to Refills and Medication was scored by summing together the 14 items after first reversing the final item to be consistent in direction with the others. Individuals were allowed to have up to 2 missing values present which were imputed with the mean of the remaining answered items, only a handful of individuals answered 13 of the 14 questions resulting in a single item within their scale being imputed across the time periods. The questionnaire has 14 items with each item being recorded on a four-point Likert scale. The total score ranges from 14-56 with the lower score indicating better adherence. |
Baseline and 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of PGx Testing
Time Frame: Baseline and 6 months
|
Acceptability of PGx testing in primary care among persons taking a target antidepressant and primary care physicians who care for them
|
Baseline and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lorriane Buis, PhD, University of Michigan Department of Family Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HUM00121185
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antidepressants Causing Adverse Effects in Therapeutic Use
-
University Hospital, CaenCompletedFall | Antidepressants Causing Adverse Effects in Therapeutic UseFrance
-
Jordan University HospitalNot yet recruitingAntibiotics Causing Adverse Effects in Therapeutic UseJordan
-
Battelle Memorial InstituteTerminatedScopolamine Causing Adverse Effects in Therapeutic UseUnited States
-
WockhardtClinartis, LLCCompletedAntibiotics Causing Adverse Effects in Therapeutic UseUnited States
-
Assiut UniversityCompletedKetamine Causing Adverse Effects in Therapeutic UseEgypt
-
University of WashingtonCompletedEpinephrine Causing Adverse Effects in Therapeutic UseUnited States
-
Methodist Health SystemEnrolling by invitationAntibiotics Causing Adverse Effects in Therapeutic UseUnited States
-
Stephane CookCompletedAspirin Causing Adverse Effects in Therapeutic UseSwitzerland
-
South Valley UniversityNot yet recruitingSpinal Anesthetics Causing Adverse Effects in Therapeutic Use
-
The University of QueenslandNational Health and Medical Research Council, AustraliaRecruitingAntibiotics Causing Adverse Effects in Therapeutic Use | Antimicrobial StewardshipAustralia
Clinical Trials on PGx test
-
Mayo ClinicNot yet recruitingSide Effect of Drug | Pharmacogenomic Drug Interaction | Drug Metabolism, Poor, CYP2D6-Related | Ineffective Drug Action | Drug Metabolism, Poor, CYP2C19-RelatedUnited States
-
AltheaDxInnovis LLCCompletedDepression | AnxietyUnited States
-
AltheaDxCarolina Partners in Mental HealthcareCompletedDepression | AnxietyUnited States
-
Azienda Socio Sanitaria Territoriale degli Spedali...IRCCS Istituto Centro San Giovanni di Dio- FatebenefratelliRecruitingMajor Depressive DisorderItaly
-
AltheaDxOchsner Health SystemTerminatedSurgery | Acute PainUnited States
-
AltheaDxUniversity Hospitals Cleveland Medical CenterCompleted
-
Duke UniversityNational Institute of General Medical Sciences (NIGMS)Completed
-
Brigham and Women's HospitalCQuentia NGS, LLCWithdrawnPerioperative/Postoperative ComplicationsUnited States
-
Glycemic Index Laboratories, IncCanadian Center for Functional Medicine; InovoBiologic Inc.CompletedBlood Glucose, PostprandialCanada
-
Duke UniversityCompletedPharmacogenetics | Medication Therapy ManagementUnited States